Bisphosphonate treatment of pediatric bone disease

Phyllis W. Speiser, Cheril L. Clarson, Erica Eugster, Stephen F. Kemp, Sally Radovick, Alan D. Rogol, Thomas A. Wilson

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The science of measuring bone mineral density has developed rapidly and, with it, an improved understanding of the efficacy and safety of various therapeutic interventions in adults. In contrast, the meaning and precision of such measurements in children are equivocal, and the concept of treatment for low bone density in the young patient is still largely undecided. In this report we review the present state of knowledge regarding the use of bisphosphonates during childhood to ameliorate the skeletal abnormalities associated with osteogenesis imperfecta, idiopathic juvenile osteoporosis, fibrous dysplasia of bone and cerebral palsy. Because of the paucity of long-term studies among children regarding the safety and efficacy of these drugs, it is difficult to formulate strong evidence-based recommendations for their use, except perhaps in children with osteogenesis imperfecta.

Original languageEnglish
Pages (from-to)87-96
Number of pages10
JournalPediatric Endocrinology Reviews
Volume3
Issue number2
StatePublished - Dec 2005

Fingerprint

Bone Diseases
Diphosphonates
Osteogenesis Imperfecta
Pediatrics
Bone Density
Fibrous Dysplasia of Bone
Safety
Cerebral Palsy
Therapeutics
Pharmaceutical Preparations

Keywords

  • Bone density
  • Cerebral palsy
  • Disphosphonates
  • Fibrous dysplasia
  • Idiopathic juvenile osteoporosis
  • Metabolic bone disease
  • Osteogenesis imperfecta
  • Osteoporosis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Speiser, P. W., Clarson, C. L., Eugster, E., Kemp, S. F., Radovick, S., Rogol, A. D., & Wilson, T. A. (2005). Bisphosphonate treatment of pediatric bone disease. Pediatric Endocrinology Reviews, 3(2), 87-96.

Bisphosphonate treatment of pediatric bone disease. / Speiser, Phyllis W.; Clarson, Cheril L.; Eugster, Erica; Kemp, Stephen F.; Radovick, Sally; Rogol, Alan D.; Wilson, Thomas A.

In: Pediatric Endocrinology Reviews, Vol. 3, No. 2, 12.2005, p. 87-96.

Research output: Contribution to journalArticle

Speiser, PW, Clarson, CL, Eugster, E, Kemp, SF, Radovick, S, Rogol, AD & Wilson, TA 2005, 'Bisphosphonate treatment of pediatric bone disease', Pediatric Endocrinology Reviews, vol. 3, no. 2, pp. 87-96.
Speiser PW, Clarson CL, Eugster E, Kemp SF, Radovick S, Rogol AD et al. Bisphosphonate treatment of pediatric bone disease. Pediatric Endocrinology Reviews. 2005 Dec;3(2):87-96.
Speiser, Phyllis W. ; Clarson, Cheril L. ; Eugster, Erica ; Kemp, Stephen F. ; Radovick, Sally ; Rogol, Alan D. ; Wilson, Thomas A. / Bisphosphonate treatment of pediatric bone disease. In: Pediatric Endocrinology Reviews. 2005 ; Vol. 3, No. 2. pp. 87-96.
@article{d0aeb7766bfc4ac790c1a6c69319b309,
title = "Bisphosphonate treatment of pediatric bone disease",
abstract = "The science of measuring bone mineral density has developed rapidly and, with it, an improved understanding of the efficacy and safety of various therapeutic interventions in adults. In contrast, the meaning and precision of such measurements in children are equivocal, and the concept of treatment for low bone density in the young patient is still largely undecided. In this report we review the present state of knowledge regarding the use of bisphosphonates during childhood to ameliorate the skeletal abnormalities associated with osteogenesis imperfecta, idiopathic juvenile osteoporosis, fibrous dysplasia of bone and cerebral palsy. Because of the paucity of long-term studies among children regarding the safety and efficacy of these drugs, it is difficult to formulate strong evidence-based recommendations for their use, except perhaps in children with osteogenesis imperfecta.",
keywords = "Bone density, Cerebral palsy, Disphosphonates, Fibrous dysplasia, Idiopathic juvenile osteoporosis, Metabolic bone disease, Osteogenesis imperfecta, Osteoporosis",
author = "Speiser, {Phyllis W.} and Clarson, {Cheril L.} and Erica Eugster and Kemp, {Stephen F.} and Sally Radovick and Rogol, {Alan D.} and Wilson, {Thomas A.}",
year = "2005",
month = "12",
language = "English",
volume = "3",
pages = "87--96",
journal = "Pediatric Endocrinology Reviews",
issn = "1565-4753",
publisher = "YS Medical Media Ltd.",
number = "2",

}

TY - JOUR

T1 - Bisphosphonate treatment of pediatric bone disease

AU - Speiser, Phyllis W.

AU - Clarson, Cheril L.

AU - Eugster, Erica

AU - Kemp, Stephen F.

AU - Radovick, Sally

AU - Rogol, Alan D.

AU - Wilson, Thomas A.

PY - 2005/12

Y1 - 2005/12

N2 - The science of measuring bone mineral density has developed rapidly and, with it, an improved understanding of the efficacy and safety of various therapeutic interventions in adults. In contrast, the meaning and precision of such measurements in children are equivocal, and the concept of treatment for low bone density in the young patient is still largely undecided. In this report we review the present state of knowledge regarding the use of bisphosphonates during childhood to ameliorate the skeletal abnormalities associated with osteogenesis imperfecta, idiopathic juvenile osteoporosis, fibrous dysplasia of bone and cerebral palsy. Because of the paucity of long-term studies among children regarding the safety and efficacy of these drugs, it is difficult to formulate strong evidence-based recommendations for their use, except perhaps in children with osteogenesis imperfecta.

AB - The science of measuring bone mineral density has developed rapidly and, with it, an improved understanding of the efficacy and safety of various therapeutic interventions in adults. In contrast, the meaning and precision of such measurements in children are equivocal, and the concept of treatment for low bone density in the young patient is still largely undecided. In this report we review the present state of knowledge regarding the use of bisphosphonates during childhood to ameliorate the skeletal abnormalities associated with osteogenesis imperfecta, idiopathic juvenile osteoporosis, fibrous dysplasia of bone and cerebral palsy. Because of the paucity of long-term studies among children regarding the safety and efficacy of these drugs, it is difficult to formulate strong evidence-based recommendations for their use, except perhaps in children with osteogenesis imperfecta.

KW - Bone density

KW - Cerebral palsy

KW - Disphosphonates

KW - Fibrous dysplasia

KW - Idiopathic juvenile osteoporosis

KW - Metabolic bone disease

KW - Osteogenesis imperfecta

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=32244434267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32244434267&partnerID=8YFLogxK

M3 - Article

C2 - 16361982

AN - SCOPUS:32244434267

VL - 3

SP - 87

EP - 96

JO - Pediatric Endocrinology Reviews

JF - Pediatric Endocrinology Reviews

SN - 1565-4753

IS - 2

ER -